---
title: "Genmab (GMAB) Receives a Hold from Morgan Stanley"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293621550.md"
description: "Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab (GMAB) with a $33 price target. This follows a recent Buy upgrade from TD Cowen, though TD Cowen also issued a separate Hold rating on July 13. Frommer, a 4-star analyst covering healthcare stocks, has a 55.33% success rate."
datetime: "2026-07-23T12:57:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293621550.md)
  - [en](https://longbridge.com/en/news/293621550.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293621550.md)
generator: "portal-rs"
---

# Genmab (GMAB) Receives a Hold from Morgan Stanley

Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab today and set a price target of $33.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Frommer is a 4-star analyst with an average return of 4.6% and a 55.33% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Incyte, Kymera Therapeutics, and Celldex.

In addition to Morgan Stanley, Genmab also received a Hold from TD Cowen’s Yaron Werber in a report issued on July 13. However, yesterday, TD Cowen upgraded Genmab (NASDAQ: GMAB) to a Buy.

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [KYMR.US](https://longbridge.com/en/quote/KYMR.US.md)
- [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)](https://longbridge.com/en/news/295329030.md)
- [Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMAB](https://longbridge.com/en/news/294575607.md)
- [Genmab Updates Articles of Association, Expands Capital-Raising Flexibility](https://longbridge.com/en/news/295678408.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)
- [Genmab’s Earnings Call Highlights Growth, Upgraded Outlook](https://longbridge.com/en/news/295165401.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**